AKT1 and glioblastoma: Currently, the predominant chemotherapeutic compounds employed in the management of GBM are small molecules designed to intervene with specific aberrant signaling pathways within GBM cells, including receptor tyrosine kinase activity, the PI3K/AKT/mTOR cascade, the cellular response to DNA damage, TP53 function, and inhibitors of the cell cycle [200].